Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Biochemistry and Biophysics Reports|February 16, 2016
Steroidogenesis and early response gene expression in MA-10 Leydig tumor cells following heterologous receptor down-regulation and cellular desensitizationTsuey-Ming Chen, Frank S Czerwiec, David PuettJournal of Clinical Pharmacology|February 21, 2017
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 TrialSusan E Shoaf, Arlene B Chapman, Vicente E Torres, et al.Kidney International Reports|December 23, 2017
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4Olivier Devuyst, Arlene B Chapman, Susan E Shoaf, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 15, 2016
Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT)Joseph G Verbalis, Howard Ellison, Mary Hobart, et al.European Journal of Endocrinology|February 15, 2011
Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretionJoseph G Verbalis, Suzanne Adler, Robert W Schrier, et al.The New England Journal of Medicine|November 16, 2006
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremiaRobert W Schrier, Peter Gross, Mihai Gheorghiade, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 22, 2016
Prevalence of autosomal dominant polycystic kidney disease in the European UnionCynthia J Willey, Jaime D Blais, Anthony K Hall, et al.Clinical Kidney Journal|February 13, 2019
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney diseaseMarie E Edwards, Jaime D Blais, Frank S Czerwiec, et al.Cancer Medicine|March 3, 2017
Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trialsRichard J Gralla, Fatima Ahmad, Jaime D Blais, et al.Kidney International Reports|June 11, 2020
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKDRonald D Perrone, Arlene B Chapman, Dorothee Oberdhan, et al.Pageof 5